Outcomes in patients (pts) with advanced urothelial carcinoma (aUC) treated with enfortumab vedotin (EV) after switch maintenance avelumab (MAv) in the UNITE study.

被引：9

作者：

Nizam, Amanda ^{[1
]}

Jindal, Tanya ^{[2
]}

Jiang, Cindy Y. ^{[3
]}

Alhalabi, Omar ^{[4
]}

Bakaloudi, Dimitra Rafailia ^{[5
]}

Talukder, Rafee ^{[6
]}

Davidsohn, Matthew P. ^{[7
]}

Nguyen, Charles B. ^{[8
]}

Oh, Eugene ^{[9
]}

Taylor, Amy K. ^{[10
]}

Lemke, Emily ^{[11
]}

Kilari, Deepak ^{[12
]}

Hoimes, Christopher J. ^{[13
]}

Emamekhoo, Hamid ^{[14
]}

Gupta, Shilpa ^{[15
]}

Bellmunt, Joaquim ^{[16
]}

Grivas, Petros ^{[17
,18
]}

Campbell, Matthew T. ^{[19
]}

Alva, Ajjai Shivaram ^{[20
]}

Koshkin, Vadim S. ^{[21
]}

机构：

[1] Cleveland Clin, Cleveland, OH USA

[2] Univ Calif San Francisco, Helen Diller Family Comprehens Canc Ctr, San Francisco, CA USA

[3] Univ Texas MD Anderson Canc Ctr, Hematol Oncol Fellowship, Houston, TX USA

[4] Univ Texas MD Anderson Canc Ctr, Dept Genitourinary Med Oncol, Houston, TX USA

[5] Univ Washington, Dept Med, Div Oncol, Seattle, WA USA

[6] Baylor Coll Med, Houston, TX USA

[7] Albert Einstein Coll Med, New York, NY USA

[8] Univ Michigan, Rogel Comprehens Canc Ctr, Ann Arbor, MI USA

[9] Univ Michigan, Sch Med, Ann Arbor, MI USA

[10] Univ Wisconsin Hosp & Clin, Madison, WI USA

[11] Med Coll Wisconsin, Milwaukee, WI USA

[12] Med Coll Wisconsin, Dept Med, Div Hematol & Oncol, Milwaukee, WI USA

[13] Duke Univ, Duke Canc Inst, Durham, NC USA

[14] Univ Wisconsin, Carbone Canc Ctr, Madison, WI USA

[15] Cleveland Clin, Taussig Canc Inst, Cleveland, OH USA

[16] Dana Farber Canc Inst, Boston, MA USA

[17] Univ Washington, Div Hematol & Oncol, Seattle, WA USA

[18] Fred Hutchinson Canc Ctr, Seattle, WA USA

[19] Univ Texas MD Anderson Canc Ctr, Houston, TX USA

[20] Univ Michigan, Dept Internal Med, Div Hematol & Oncol, Ann Arbor, MI USA

[21] Univ Calif San Francisco, Dept Med, Div Hematol & Oncol, San Francisco, CA USA

来源：

JOURNAL OF CLINICAL ONCOLOGY | 2024年 / 42卷 / 4_SUPPL期

关键词：

283-183-138-12099; 613-135-2370-7650-2700; 6; 5; 3224; 1880; 62; 295; 3; 1; 38092-23700;

D O I：

10.1200/JCO.2024.42.4_suppl.537

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

引用

页码：537 / 537

页数：1

共 50 条

[31] Phase 2 Trial of Enfortumab Vedotin in Patients With Previously Treated Locally Advanced or Metastatic Urothelial Carcinoma in China
Li, Siming
Shi, Yanxia
Dong, Haiying
Guo, Hongqian
Xie, Yu
Sun, Zhongquan
Zhang, Xiaoping
Kim, Eric
Zhang, Jun
Li, Yue
Xu, Chenming
Kadeerbai, Haishan
Lee, Sue
Gorla, Seema
Guo, Jun
Sheng, Xinan
CANCER MEDICINE, 2024, 13 (21):
[32] Study EV-103: Durability results of enfortumab vedotin plus pembrolizumab for locally advanced or metastatic urothelial carcinoma.
Rosenberg, Jonathan E.
Flaig, Thomas W.
Friedlander, Terence W.
Milowsky, Matthew, I
Srinivas, Sandy
Petrylak, Daniel Peter
Merchan, Jaime R.
Bilen, Mehmet Asim
Carret, Anne-Sophie
Yuan, Nancy
Sasse, Carolyn
Hoimes, Christopher J.
JOURNAL OF CLINICAL ONCOLOGY, 2020, 38 (15)
[33] Clinical outcomes of patients with metastatic urothelial carcinoma (mUC) discontinuing enfortumab vedotin (EV) monotherapy (mono) without disease progression
Sternschuss, M.
Whiting, K.
Teo, M. Y.
Bajorin, D.
Kotecha, R.
Laccetti, A. L.
Xiao, H.
Feld, E.
McHugh, D. J.
Keegan, N.
Apollo, A.
Owens, C.
Funt, S. A.
Shah, N. J.
Iyer, G.
Aggen, D. H.
Ostrovnaya, I.
Rosenberg, J. E.
ANNALS OF ONCOLOGY, 2024, 35 : S1157 - S1158
[34] Study EV-103: Preliminary durability results of enfortumab vedotin plus pembrolizumab for locally advanced or metastatic urothelial carcinoma
Rosenberg, Jonathan E.
Flaig, Thomas W.
Friedlander, Terence W.
Milowsky, Matthew I.
Srinivas, Sandy
Petrylak, Daniel Peter
Merchan, Jaime R.
Bilen, Mehmet Asim
Carret, Anne-Sophie
Yuan, Nancy
Sasse, Carolyn
Hoimes, Christopher J.
JOURNAL OF CLINICAL ONCOLOGY, 2020, 38 (06)
[35] Avelumab first-line (1L) maintenance for advanced urothelial carcinoma (aUC): Long-term outcomes from the JAVELIN Bladder 100 trial in older patients (pts)
Gupta, S.
Climent Duran, M. A.
Sridhar, S.
Powles, T. B.
Bellmunt, J.
Tyroller, K.
Guenther, S.
di Pietro, A.
Grivas, P.
ANNALS OF ONCOLOGY, 2023, 34 : S1207 - S1207
[36] Full analysis from AVENANCE: A real-world study of avelumab first-line (1L) maintenance treatment in patients (pts) with advanced urothelial carcinoma (aUC).
Barthelemy, Philippe
Loriot, Yohann
Voog, Eric
Eymard, Jean Christophe
Ravaud, Alain
Flechon, Aude
Jaillon, Christine Abraham
Chasseray, Matthieu
Lorgis, Veronique
Hilgers, Werner
Gobert, AurElien
Le Moulec, Sylvestre
Simon, Camille
Nicolas, Emanuel
Escande, Anne
Pouessel, Damien
Josse, Constant
Solbes, Marie-Noelle
Lambert, Prisca
Thibault, Constance
JOURNAL OF CLINICAL ONCOLOGY, 2023, 41
[37] EV-301: Phase Ill study to evaluate enfortumab vedotin (EV) versus chemotherapy in patients with previously treated locally advanced or metastatic urothelial cancer (Ia/mUC).
Petrylak, Daniel Peter
Rosenberg, Jonathan E.
Duran, Ignacio
Loriot, Yohann
Sonpavde, Guru
Wu, Chunzhang
Gartner, Elaina M.
Melhem-Bertrandt, Amal
Powles, Thomas
JOURNAL OF CLINICAL ONCOLOGY, 2019, 37 (07)
[38] BT8009 monotherapy in enfortumab vedotin (EV)-naive patients (pts) with metastatic urothelial carcinoma (mUC): Updated results of Duravelo-1
Reig Torras, O.
Crouzet, L.
Necchi, A.
Baldini, C.
Lostes Bardaji, M. J.
Doger de Speville, B.
Italiano, A.
Verlingue, L.
Boni, V.
Carter, L.
Duran, I.
Garmezy, B.
Galsky, M. D.
Falchook, G. S.
DeMars, L.
Josephs, K.
Xu, C.
Bader, J.
Fontana, E.
ANNALS OF ONCOLOGY, 2024, 35 : S515 - S516
[39] Primary results of EV-301: A phase III trial of enfortumab vedotin versus chemotherapy in patients with previously treated locally advanced or metastatic urothelial carcinoma.
Powles, Thomas
Rosenberg, Jonathan E.
Sonpavde, Guru
Loriot, Yohann
Duran, Ignacio
Lee, Jae-Lyun
Matsubara, Nobuaki
Vulsteke, Christof
Wu Chunzhang
Campbell, Mary S.
Matsangou, Maria
Petrylak, Daniel Peter
JOURNAL OF CLINICAL ONCOLOGY, 2021, 39 (06)
[40] Patient-reported outcomes (PROs) in cisplatin-ineligible patients (pts) with locally advanced or metastatic urothelial cancer (la/mUC) treated with enfortumab vedotin (EV) alone or in combination with pembrolizumab (P) in the phase 1b/2 EV-103 Cohort K study.
Milowsky, Matthew I.
O'Donnell, Peter H.
Hoimes, Christopher J.
Petrylak, Daniel P.
Flaig, Thomas W.
Moon, Helen H.
Friedlander, Terence W.
Mar, Nataliya
McKay, Rana R.
Srinivas, Sandy
Gravis, Gwenaelle
Ramamurthy, Chethan
Bupathi, Manojkumar
Bracarda, Sergio
Wright, Phoebe
Carret, Anne-Sophie
Yu, Yao
Matsuda, Tara
Kataria, Ritesh S.
Rosenberg, Jonathan E.
JOURNAL OF CLINICAL ONCOLOGY, 2023, 41

← 1 2 3 4 5 →